Kwetina (Quetiapine)

Quetiapine acts as an antagonist at several neurotransmitter receptors, notably serotonin 5‑HT2A and dopamine D2 receptors, while also blocking histamine H1, adrenergic α1 and other receptors. This receptor profile modulates dopaminergic and serotonergic pathways, reducing psychotic symptoms, stabilizing mood, and enhancing antidepressant effects.

The appropriate dose of Kwetina is determined individually by the prescribing clinician based on the specific indication, patient age, response, and tolerability. Dosage may be started low and titrated upward, but exact amounts and schedules should be obtained from the treating physician’s prescription.

Quetiapine is classified as pregnancy category B1 in the EU, indicating no evidence of fetal risk in animal studies, but human data are limited. It should only be used during pregnancy or lactation if the potential benefit outweighs the risk, and under close medical supervision.

To request Kwetina, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older typical antipsychotics, quetiapine has a broader receptor profile that often results in lower rates of extrapyramidal symptoms but may cause more sedation and metabolic effects. Relative to other atypicals such as risperidone or olanzapine, its efficacy in psychosis is comparable, while its side‑effect profile differs, influencing clinician choice.

Kwetina should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablet appears discolored.

Kwetina is taken orally, usually with or without food, as directed by the prescribing physician. Tablets should be swallowed whole with a glass of water and not chewed or crushed, unless a specific formulation permits it. Consistent timing each day helps maintain stable drug levels.

The most serious adverse reactions to quetiapine include neuroleptic malignant syndrome, agranulocytosis, severe hypotension, tardive dyskinesia, and suicidal thoughts, particularly when initiating therapy or adjusting dose. Patients should be monitored closely for these events, and any concerning symptoms require immediate medical attention.

Kwetina is contraindicated in patients with known hypersensitivity to quetiapine or any of its excipients. It should be used with caution, or avoided, in individuals with uncontrolled cardiovascular disease, severe hepatic impairment, or a history of neuroleptic malignant syndrome. Pregnant or breastfeeding women should only use it when clearly indicated by a healthcare professional.